HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy

doi:10.1038/s41598-017-14990-w

Paper

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy

Published Nov 2, 2017 · Antonella Mangraviti, Tula P. Raghavan, F. Volpin

Scientific Reports

Q1 SJR score

67

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Acriflavine, a HIF-1 inhibitor, provides nearly 100% long-term survival and radiological tumor response in brain cancer therapy, highlighting the importance of HIF-1-targeting molecules in brain tumor therapy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy

References

Citations